



Core One Labs Announces Anticipated Release Date of 2020 Second Quarter Results

Vancouver, British Columbia, Canada – September 29, 2020 – **Core One Labs Inc.** (CSE: COOL), (OTCQX: CLABD), (Frankfurt: LD62, WKN: A2P8K3) (the “**Company**”) announces that further to its news release dated August 27, 2020, the Company is expecting to file its second quarter financial statements and management’s discussion and analysis for the period ended June 30, 2020 (the “Interim Filings”) by the extension date of October 15, 2020 pursuant to exemptive relief granted by Canadian securities regulatory authorities that allows it to delay the filing of its annual documents required by sections 4.2 and 5.12(2) of *National Instrument 51-102 (“NI 51-102”)*. In response to the coronavirus disease pandemic, securities regulatory authorities in Canada have granted a blanket exemption allowing issuers an additional 45 days to complete their regulatory filings.

The Company is relying on blanket relief granted by Canadian securities regulatory authorities under *BC Instrument 51-515* allowing issuers an additional 45 days to complete their regulatory filings required pursuant to sections 4.3 and 5.12(2) of *National Instrument 51-102* by August 31, 2020. The Company is continuing to work diligently to file the Interim Filings at its earliest opportunity, which is expected to occur on or before October 15, 2020.

Until such time as the Interim Filings are filed, the Company’s management and insiders are subject to a trading blackout that reflects the principals contained in section 9 of *National Policy 11-207 – Failure-to-File Cease Trade Orders and Revocations in Multiple Jurisdictions*.

About Core One Labs Inc.

Core One Labs Inc. is a research and technology company with a state-of-the-art cannabis production and packaging facility located in Southern California. The Company’s technology produces infused strips (like breath strips) that are not only a safer, healthier option to other forms of delivery but also superior bioavailability of cannabis constituents. The technology provides a new way to accurately meter the dosage and assure the purity of selected product. The Company holds an interest in walk-in medical clinics located in Vancouver and West Vancouver, British Columbia which maintain a database of over 200,000 patients combined. The Company intends to further develop its product offerings through research and development in these clinics, including the integration of intellectual property related to psychedelic treatments and novel drug therapies.

Core One Labs Inc.

Joel Shacker
Chief Executive Officer

FOR MORE INFORMATION, PLEASE CONTACT:

info@core1labs.com
1-866-347-5058

Cautionary Disclaimer Statement:

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to the Company's limited operating history and the need to comply with environmental and governmental regulations. In addition, marijuana remains a Schedule I drug under the United States Controlled Substances Act of 1970. Although Congress has prohibited the US Justice Department from spending federal funds to interfere with the implementation of state medical marijuana laws, this prohibition must be renewed each year to remain in effect. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.